(1.天津医科大学肿瘤医院检验科,国家肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津300060;2.天津市宝坻区人民医院检验科,天津医科大学宝坻临床学院,天津301800)
Objective: To explore diagnostic significance of TuM2-PK, tPSA, fPSA/tPSA and PSAD for prostate cancer in PSA gray area. Methods: Two hundred and fifty-two cases with prostatic cancer (PCa), benign prostatic hyperplasia (BPH) and prostatitis whose tPSA levels were between 4 ng/mL and 10 ng/mL were chosen. Plasmatic TuM2-PK and serum fPSA, tPSA were examined. Prostate volume was determined by transrectal ultrasound. PSAD and fPSA/tPSA were calculated. The diagnostic significance of TuM2-PK, tPSA, fPSA/tPSA and PSAD for PCa in PSA gray area were analyzed using SPSS19.0. Results: Compared with BPH group and elderly prostatitis group, TuM2-PK, fPSA/tPSA and PSAD in PCa group were significantly changed (P<0.05); There was no significant difference in tPSA among the three groups. The AUC of these indexes in descending order was TuM2-PK, PSAD, fPSA/tPSA, and tPSA. While the cutoffs of TuM2-PK, tPSA, fPSA/tPSA and PSAD were 24.30 U/mL, 6.60 ng/mL, 0.16 and 0.15 ng/mL/cm3, the sensitivity and specificity of diagnosed PCa were 88.9% and 92.1%,72.2% and 44.9%,80.5% and 60.2%,83.3% and 71.8%, respectively. Conclusion: TuM2-PK, fPSA/tPSA and PSAD can increase sensitivity and specificity inthediagnosis of PCa in PSA gray area. And compared with fPSA/tPSA and PSAD, TuM2-PK is more accurate in diagnosing PCa.
?
[1] 丁茗敏. 应用血清PSA进行前列腺癌筛查的意义[J]. 中国疗养医学, 2011,20(2):160 [2] Greene K L, Albertsen P C, Babaian R J, et al. Prostate specific antigen best practice statement: 2009 update[J]. J Urol, 2013,189(1 Suppl):S2 [3] 杨娜, 杨琳, 刘禄, 等. 探讨tPSA,fPSA,f/tPSA和PSAD对PSA灰区前列腺癌的诊断价值[J]. 临床医药实践, 2014,23(1):14 [4] Amirrasouli H, Kazerouni F, Sanadizade M, et al. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population[J]. Urol J, 2010,7(2):99 [5] 范本, 齐范, 李文泽, 等. 湖南地区不同年龄、不同前列腺体积与血清中PSA及fPSA水平的相关性研究[J]. 实用预防医学, 2011,18(11):2034 [6] Li J, Yang Z, Zou Q, et al. PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer[J]. Clin Transl Oncol, 2014,16(2):200 [7] Fatela-Cantillo D, Fernandez-Suarez A, Moreno M A, et al. Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients[J]. Tumour Biol, 2012,33(3):825 [8] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015,65(1):5 [9] Liu Z Y, Sun Y H, Xu C L, et al. Age-specific PSA reference ranges in Chinese men without prostate cancer[J]. Asian J Androl, 2009,11(1):100 [10] 马志远, 赵林海, 王阳, 等. PSA密度对TPSA灰区前列腺癌的诊断意义[J]. 临床泌尿外科杂志, 2011,26(2):132 . [11] 贺乐乐, 魏伟, 杨进益. PSA及其相关指数对前列腺癌诊断价值的研究进展[J]. 现代泌尿生殖肿瘤杂志, 2015,7(3):190 [12] Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells[J]. Int J Biochem Cell Biol, 2011,43(7):969 [13] Chaneton B, Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer[J]. Trends Biochem Sci, 2012,37(8):309 [14] Morgan H P, O’Reilly F J, Wear M A, et al. M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation[J]. Proc Natl Acad Sci U S A, 2013,110(15):5881 [15] Gui D Y, Lewis C A, Vander H M . Allosteric regulation of PKM2 allows cellular adaptation to different physiological states[J]. Sci Signal, 2013,6(263):1290 [16] Gao X, Wang H, Yang J J, et al. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase[J]. Mol Cell, 2012,45(5):598 [17] Feng C, Gao Y, Wang C, et al. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2013,98(9):E1524 [18] 刘东林. 特拉唑嗪联合松花粉治疗慢性前列腺炎临床观察[J]. 山西医药杂志, 2014,43(19):2320 [19] Moller-Nielsen C, Sell A. Granulomatous prostatitis. Differential diagnosis from cancer of the prostate[J]. Ugeskr Laeger, 1983,145(13):994
?
[1]魏强,齐灿,罗飞,等.转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析[J].天津医科大学学报,2013,19(05):390.
[2]杨帮东,姜行康,齐 灿,等.尿液中PCA3评分对前列腺癌早期诊断的临床意义[J].天津医科大学学报,2013,19(06):487.
YANG Bang-dong,JIANG Xing-kang,QI Can,et al.Clinical significance of urinary PCA3 score to diagnose prostate cancer[J].Journal of Tianjin Medical University,2013,19(02):487.
[3]刘利维,刘春雨. MicroRNAs 与前列腺癌的表观遗传学研究进展[J].天津医科大学学报,2014,20(01):74.
[4]王 超,余泉峰,徐 勇,等.经直肠超声造影诊断前列腺癌的临床分析[J].天津医科大学学报,2014,20(05):375.
WANG Chao,YU Quan-feng,XU Yong,et al.Clinical analysis of contrast-enhanced transrectal ultrasonography for the diagnosis of prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):375.
[5]张晓会,张志宏,徐 勇,等.合并症对局限性或局部晚期前列腺癌患者早期生存的影响[J].天津医科大学学报,2014,20(05):379.
ZHANG Xiao-hui,ZHANG Zhi-hong,XU Yong,et al. Influence of complications on early survival of patients with localized or locally advanced prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):379.
[6]盛 镔,张 蒙,马鹏德,等.核糖体蛋白L37在前列腺癌中的表达及临床意义[J].天津医科大学学报,2015,21(05):401.
SHENG Bin,ZHANG Meng,MA Peng-de,et al.Expression of ribosomal protein L37 in prostate cancer and its clinical significance[J].Journal of Tianjin Medical University,2015,21(02):401.
[7]李 江,张恩龙,赵 阳,等.前列腺癌靶向磁共振成像和光热治疗的实验研究[J].天津医科大学学报,2017,23(02):93.
LI Jiang,ZHANG En-long,ZHAO Yang,et al.?Experimental research of targeted magnetic resonance imaging and photo thermal therapy for prostate cancer [J].Journal of Tianjin Medical University,2017,23(02):93.
[8]张一然,潘盼,连振鹏,等.磁共振扫描对经直肠超声引导前列腺穿刺活检的影响[J].天津医科大学学报,2017,23(02):99.
ZHANG Yi-ran,PAN Pan,LIAN Zhen-peng,et al.Effect of magnetic resonance imaging scan on the?transrectal ultrasound?prostate biopsy[J].Journal of Tianjin Medical University,2017,23(02):99.
[9]薄志强,孙桂江,王 丽,等.CtBP2异常表达对前列腺癌PC3细胞增殖效应影响的研究[J].天津医科大学学报,2017,23(02):103.
BO Zhi-qiang,SUNGui-jiang,WANG Li,et al.Effect of abnormal expression of CtBP2 on the proliferation of prostate cancer cell line PC3[J].Journal of Tianjin Medical University,2017,23(02):103.
[10]徐庆祝,牛远杰.Gleason 10分前列腺癌患者临床特点分析[J].天津医科大学学报,2017,23(04):361.
XU Qing-zhu,NIU Yuan-jie.Clinical and pathological research of prostate cancer with Gleason score 10[J].Journal of Tianjin Medical University,2017,23(02):361.